Oct
2026
Fiera Milano, Italy
Visit us
stand 5D66, Integrated Pharma

A.forall

Exhibitor at CPHI Milan 2026
About Us

A.forall Group is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and offices in Ireland and the United States. Employing in total 144 employees, the group distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. At the same time, A.forall is a global player on the generics market, with around 30 molecules on the European and US market and a fully stocked pipeline of niche, complex and added value products. 

Neogen and Milla Pharmaceuticals are A.forall companies.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Belgium
  • On CPHI since:
    2022
  • Certificates:
    1
  • Employees:
    100 - 249
Company types
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Generic APIs producer
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Regulatory Affairs
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 5D66, Integrated Pharma

Products Featured at CPHI Milan 2026

  • Azelastine+Fluticasone nasal spray 137/50 mcg/dose

    Product Azelastine+Fluticasone nasal spray 137/50 mcg/dose

    Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
  • Sumatriptan solution for injection in autoinjector 6mg/0,5 (single dose)

    Product Sumatriptan solution for injection in autoinjector 6mg/0,5 (single dose)

    Subcutaneous sumatriptan has been considered as the most efficacious treatment in the acute phase of migraine both on pain alone as well as on associated autonomic symptoms.
  • Edoxaban filmcoated tablets 15mg, 30 mg & 60 mg

    Product Edoxaban filmcoated tablets 15mg, 30 mg & 60 mg

    Edoxaban is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). 

    ...
  • Fluticasone Furoate nasal spray 27.5 mcg/dose

    Product Fluticasone Furoate nasal spray 27.5 mcg/dose

    It is indicated in adults, adolescents and children (6 years and over)

    It is indicated for the treatment of the symptoms of allergic rhinitis.

  • Dexmedetomidine ready to use, 4mcg/ml (vial)

    Product Dexmedetomidine ready to use, 4mcg/ml (vial)

    For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
    For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical ...